CD8A and breast cancer: PhenoAgeAccel was associated with breast cancer incidence in both the Sister Study and EPIC cohorts [24, 33], and DNAm estimators of circulating CD8+ T cells and monocytes appear to be time‐dependent markers of breast cancer risk [31].